

Placebo Publications February 2018

1. Ballard, E. D., Yarrington, J. S., Farmer, C. A., Lener, M. S., Kadriu, B., Lally, N., Williams, D., Machado-Vieira, R., Niciu, M. J., Park, L., & Zarate Jr., C. A. (2018). Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. *J Affect Disord*, 231, 51-57. doi:10.1016/j.jad.2018.01.027
<https://www.ncbi.nlm.nih.gov/pubmed/29448238>
2. Borghi, C., & Veronesi, M. (2018). Cough and ACE Inhibitors: The Truth Beyond Placebo. *Clin Pharmacol Ther*. doi:10.1002/cpt.1040
<https://www.ncbi.nlm.nih.gov/pubmed/29468656>
3. Bräscher, A.-K., Witthöft, M., & Becker, S. (2018). The Underestimated Significance of Conditioning in Placebo Hypoalgesia and Nocebo Hyperalgesia. *Pain Research and Management*, 2018, 1-8. doi:10.1155/2018/6841985
<https://doi.org/10.1155/2018/6841985>
4. Chhetri, J. K., de Souto Barreto, P., Cantet, C., Cesari, M., Coley, N., Andrieu, S., & Vellas, B. (2018). Trajectory of the MAPT-PACC-Preclinical Alzheimer Cognitive Composite in the Placebo Group of a Randomized Control Trial: Results from the MAPT Study: Lessons for Further Trials. *J Prev Alzheimers Dis*, 5(1), 31-35. doi:10.14283/jpad.2017.21
<https://www.ncbi.nlm.nih.gov/pubmed/29405230>
5. Cohen, A., Plonsky-Toder, M., & Tirosh, E. (2018). The Short-Term Placebo Response in Children With Attention-Deficit Hyperactivity Disorder (ADHD). *J Child Neurol*, 883073818756403. doi:10.1177/0883073818756403
<https://www.ncbi.nlm.nih.gov/pubmed/29451082>
6. Fralick, M., Avorn, J., Franklin, J. M., Abdurrob, A., & Kesselheim, A. S. (2018). Application and impact of run-in studies. *J Gen Intern Med*. doi:10.1007/s11606-018-4344-7
<https://www.ncbi.nlm.nih.gov/pubmed/29450684>
7. Hall, K. T., Loscalzo, J., & Kaptchuk, T. (2018). Pharmacogenomics and the Placebo Response. *ACS Chem Neurosci*. doi:10.1021/acscchemneuro.8b00078
<https://www.ncbi.nlm.nih.gov/pubmed/29498823>
8. Hoenemeyer, T. W., Kaptchuk, T. J., Mehta, T. S., & Fontaine, K. R. (2018). Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial. *Sci Rep*, 8(1), 2784. doi:10.1038/s41598-018-20993-y
<https://www.ncbi.nlm.nih.gov/pubmed/29426869>

9. Hofler, C., Gremsl, A., & Schienle, A. (2018). Nocebo and pseudo-neglect: Paradoxical effects detected with eye-tracking. *Int J Psychophysiol*, 125, 29-34. doi:10.1016/j.ijpsycho.2018.01.014
<https://www.ncbi.nlm.nih.gov/pubmed/29410091>
10. Isawa, M., Tashiro, R., Naruse, C., Yamaguchi, Y., Itoh, H., Nishimura, T., Tomi, M., Shimada, H., Saito, H., Mochizuki, M., & Nakashima, E. (2018). Effect of serotonin transporter genotype on self-reported efficacy and activity changes of brain prefrontal area in response to placebo. *Pharmazie*, 73(1), 35-41. doi:10.1691/ph.2018.7740
<https://www.ncbi.nlm.nih.gov/pubmed/29441949>
11. Khan, A., Fahl Mar, K., Schilling, J., & Brown, W. A. (2018). Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016. *PLoS One*, 13(2), e0193043. doi:10.1371/journal.pone.0193043
<https://www.ncbi.nlm.nih.gov/pubmed/29489874>
12. Mak, D. N., Au, I. P., Chan, M., Chan, Z. Y., An, W. W., Zhang, J. H., Draper, D., & Cheung, R. T. (2018). Placebo effect of facilitatory Kinesio tape on muscle activity and muscle strength. *Physiother Theory Pract*, 1-6. doi:10.1080/09593985.2018.1441936
<https://www.ncbi.nlm.nih.gov/pubmed/29461139>
13. Novack, G. D. (2018). Compared to what? The placebo effect in dry eye therapy. *Ocul Surf*. doi:10.1016/j.jtos.2018.02.001
<https://www.ncbi.nlm.nih.gov/pubmed/29452252>
14. Richardson, M., Isbister, G., & Nicholson, B. (2018). A Novel Treatment Protocol (Nocebo Hypothesis Cognitive Behavioural Therapy; NH-CBT) for Functional Neurological Symptom Disorder/Conversion Disorder: A Retrospective Consecutive Case Series. *Behav Cogn Psychother*, 1-7. doi:10.1017/S1352465817000832
<https://www.ncbi.nlm.nih.gov/pubmed/29463338>
15. Sauvaget, A., Bulteau, S., Guilleux, A., Leboucher, J., Pichot, A., Valriviere, P., Vanelle, J. M., Sebille-Rivain, V., & Grall-Bronnec, M. (2018). Both active and sham low-frequency rTMS single sessions over the right DLPFC decrease cue-induced cravings among pathological gamblers seeking treatment: A randomized, double-blind, sham-controlled crossover trial. *J Behav Addict*, 1-11. doi:10.1556/2006.7.2018.14
<https://www.ncbi.nlm.nih.gov/pubmed/29463098>

16. Silverman, R. K., Ivanova, A., & Fine, J. (2018). Sequential parallel comparison design with binary and time-to-event outcomes. *Stat Med*. doi:10.1002/sim.7635
<https://www.ncbi.nlm.nih.gov/pubmed/29462838>
17. Tetreault, P., Baliki, M. N., Baria, A. T., Bauer, W. R., Schnitzer, T. J., & Apkarian, A. V. (2018). Inferring distinct mechanisms in the absence of subjective differences: Placebo and centrally acting analgesic underlie unique brain adaptations. *Hum Brain Mapp*. doi:10.1002/hbm.23999
<https://www.ncbi.nlm.nih.gov/pubmed/29417694>
18. van Bodegraven, A. A., & Boone, N. W. (2018). Editorial: nocebo effect and switching to biosimilars. *Aliment Pharmacol Ther*, 47(6), 850-851. doi:10.1111/apt.14509
<https://www.ncbi.nlm.nih.gov/pubmed/29446141>
19. Van Hedger, K., Keedy, S. K., Mayo, L. M., Heilig, M., & de Wit, H. (2018). Neural responses to cues paired with methamphetamine in healthy volunteers. *Neuropsychopharmacology*. doi:10.1038/s41386-017-0005-5
<https://www.ncbi.nlm.nih.gov/pubmed/29463908>
20. Wanigasekera, V., Wartolowska, K., Huggins, J. P., Duff, E. P., Vennart, W., Whitlock, M., Massat, N., Pauer, L., Rodgers, P., Hoggart, B., & Tracey, I. (2018). Disambiguating pharmacological mechanisms from placebo in neuropathic pain using functional neuroimaging. *Br J Anaesth*, 120(2), 299-307. doi:10.1016/j.bja.2017.11.064
<https://www.ncbi.nlm.nih.gov/pubmed/29406179>
21. Wartolowska, K., Beard, D., & Carr, A. (2017). Blinding in trials of interventional procedures is possible and worthwhile. *F1000Res*, 6, 1663. doi:10.12688/f1000research.12528.2
<https://www.ncbi.nlm.nih.gov/pubmed/29259763>
22. Webster, R. K., Weinman, J., & Rubin, G. J. (2018). Medicine-related beliefs predict attribution of symptoms to a sham medicine: A prospective study. *Br J Health Psychol*. doi:10.1111/bjhp.12298
<https://www.ncbi.nlm.nih.gov/pubmed/29405507>
23. Whitehouse, W. P. (2018). A quasi-placebo may have a role in some randomised controlled trials. *Trials*, 19(1), 92. doi:10.1186/s13063-018-2496-8
<https://www.ncbi.nlm.nih.gov/pubmed/29409512>
24. Zilcha-Mano, S., Roose, S. P., Brown, P. J., & Rutherford, B. R. (2018). A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials. *Am J Geriatr Psychiatry*. doi:10.1016/j.jagp.2018.01.001
<https://www.ncbi.nlm.nih.gov/pubmed/29398354>